adjuvant t-dm1 for her 2 breast cancer: critical data from the katherine study
Published 1 year ago • 634 plays • Length 5:42Download video MP4
Download video MP3
Similar videos
-
3:51
adjuvant t-dm1 therapy for early-stage her2 breast cancer
-
4:54
adjuvant t-dm1 for stage i her2 breast cancer
-
3:25
new data comparing adjuvant t-dm1 vs trastuzumab for her2 breast cancer
-
5:15
case review: t-dm1 for residual her2 breast cancer
-
6:04
katherine trial updates for her2-positive breast cancer
-
3:29
t-dm1 vs. trastuzumab as adjuvant therapy for her2-positive breast cancer
-
5:46
adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for her2-positive breast cancer
-
2:09
adjuvant therapy data for her2-positive breast cancer
-
1:18
expert discusses practice-changing data from katherine trial in breast cancer
-
2:52
5-year correlative analysis of atempt: adjuvant t-dm1 vs paclitaxel trastuzumab for stage i her2 bc
-
6:40
her2 breast cancer: managing patients on t-dm1
-
6:53
treating early her2 breast cancer: katherine
-
0:56
t-dm1 as part of our standard of care with residual her 2 disease
-
1:21
dr. louis weiner discusses the t-dm1 emilia trial for her2-positive breast cancer
-
3:48
neoadjuvant t-dm1 in early-stage her2 breast cancer
-
7:30
#esmo21 expert video report on her2-positive metastatic breast cancer
-
4:16
adjuvant treatment for stage i her2 breast cancer
-
1:31
dr. geyer on the rationale for the katherine trial in her2-positive breast cancer
-
4:19
asco: new treatment (t-dm1) for her2-positive advanced breast cancer?